brachytherapy is performed. In each patient the brachytherapy procedure is individualised to ensure target coverage and sparing of adjacent normal structures. This video demonstrates the free hand interstitial technique of a women with locally advanced vulvar cancer with distal vaginal, periurethral involvement. Also disease was close to posterior forchette and clitoris.

**Results** Free hand multilane interstitial implant was performed. After external radiation of 45/Gy/25 fractions/5 weeks additional HDR brachytherapy boost of 3.5 Gy x 4 fractions were delivered twice daily. Video demonstrates the complex implant procedure. Additionally aspects of treatment planning and implant removal will be discussed. A summary of techniques of interstitial brachytherapy will be presented. Apart from the case brachytherapy in setting of field cancerisation will also be discussed.

**Conclusion** Interstitial brachytherapy is a highly conformal and effective way of radiation dose escalation in patients with medically inoperable Ca Vulva. Further training of gynecology radiation oncology community is needed to improve outcomes in these cohorts of patients.

**2022-RA-766-ESGO**  
**CUTANEOUS VULVAR METASTASIS AFTER COMBINED TREATMENT OF CERVICAL CANCER-CASE REPORT**

1Igor Aluloski, 2Mile Tanturovski, 3Saso Stojanovski, 4Igor Samardziski, 5Slavica Kostadinova-Kunovska, 6Rubens Jovanovic, 7Dubravka Koloska, 1Operative Gynecologic Oncology, University Clinic for Obstetrics and Gynecology-Skopje, Skopje, Macedonia, The Former Yugoslav Republic of; 2Peripartal intensive care unit, University Clinic for Obstetrics and Gynecology-Skopje, Skopje, Macedonia, The Former Yugoslav Republic of; 3Institute of Pathology, Medical Faculty-Skopje, Skopje, Macedonia, The Former Yugoslav Republic of; 4University Clinic for Obstetrics and Gynecology – Skopje, Skopje, Macedonia, The Former Yugoslav Republic of

10.1136/ijgc-2022-ESGO.930

**Introduction/Background** Invasive adenosquamous carcinoma of the cervix has an incidence of only 4% of all epithelial cervical tumors. Additionally to the local invasion, this type of cancer is characterized by the appearance of distant metastases in the lungs, bones and liver, while cutaneous metastases are extremely rare.

**Methodology** We present a rare case of cutaneous vulvar metastasis originating from adenosquamous cervical cancer after combined treatment. Nine months after the operation, due to observed vulvar lesions, a clinical examination and imaging diagnostic procedures were performed. After the removal of the vulvar lesions, a histopathology report describes them as poorly differentiated adenosquamous carcinoma with identical morphological characteristics as the primary neoplasm of the cervix.

**Results** Cutaneous metastasis from carcinoma of the uterine cervix is very rare. The incidence of cutaneous metastases in treated cervical cancers is 0.8%, with a rare occurrence of cutaneous vulvar metastases, usually 3.5 to 6 years after surgical treatment. Therefore, this is a rare case of secondary metastatic deposit that occurs at an unusual localization for a relatively short period of time.

**Conclusion** Vulvar lesions in patients with previously diagnosed and treated cervical cancer need to be histologically verified in order to confirm or exclude a possible metastatic process from the primary cervical neoplasm.
and the overall detection rate was 96.9%. Twenty-one patients had SN metastases (stage III A-C) while 79 patients were node negative (stage IB). Median follow up was 20.4 month (range 2–47.8). 73% of patients had more than one and 41% of patients had more than two years follow-up. During follow-up 10 patients developed recurrence (in vulva (n=4), groin (n=1), vulva and groin (n=4) and distant metastases (n=1)). The isolated groin recurrences occurred in one patient with bilaterally SN-negative groins. The two years disease free survival and overall survival was 93.0% and 95.2%, respectively.

Conclusion A combination of fluorescent and radioactive technique using ICG-99mTc-Nanocoll for detection of SN is feasible and a safe treatment option for patients with clinically low stage vulvacan.

Abstract 2022-RA-822-ESGO Figure 1

Conclusion The percentage of HPV-positive VSCCs has increased from 1970–75 until 2000–05. The predominant genotypes are HPV 16, 33 and 18 and have not changed during the last decades. HPV-positive tumours were associated with better survival.

Abstract 2022-RA-868-ESGO

Introduction/Background Approximately 25–43% of vulvar squamous cell carcinomas (VSCC) are associated with human papillomavirus (HPV). They occur in younger women, are often of warly and basaloid histology and show a better prognosis than non-HPV cancers. The predominant genotypes are HPV 16, 33 and 18. VSCC incidence rates among women younger than 50–60 years are on the rise, partly explained by increasing exposure to HPV. However, studies on HPV-prevalence in VSCC over time are lacking. Thus, our aim was to compare HPV-prevalence and genotype distribution in Norwegian VSCC cases from 1970–75 and 2000–05 and investigate a possible prognostic role of HPV-infection.

Methodology All cases of VSCC from 1970–75 (N=153) and 2000–05 (N=199) were extracted from the Cancer Registry of Norway (N=352). Formalin-fixed, paraffin-embedded tissue blocks were retrieved and DNA was extracted. For 282 cases, HPV-DNA analysis was successfully performed. All samples were tested for 19 different genotypes, using real-time TaqMan PCR. Overall survival rates were calculated using the Kaplan Meier method. Multivariable Cox regression analysis was performed to estimate hazard ratios adjusted for age at diagnosis, FIGO stage and diagnostic period.

Results The percentage of HPV-positive cases increased significantly from 23.8% in 1970–75 to 35.3% in 2000–05 (p=0.037). The predominant genotypes detected were HPV 16 (73%), 33 (21%) and 18 (6%) in both periods. HPV-status was an independent prognostic factor with HPV-positive tumours being associated with a better prognosis, HR=0.65, 95%CI [0.48; 0.86], p=0.003. However, when adjusted for age at diagnosis, FIGO stage and diagnostic period, only higher FIGO stage remained significantly associated with higher mortality.